Hostname: page-component-669899f699-swprf Total loading time: 0 Render date: 2025-04-29T20:53:36.273Z Has data issue: false hasContentIssue false
  • English
  • Français

Tryptamine Metabolism in Depression

Published online by Cambridge University Press:  29 January 2018

A. Coppen ,
D. M. Shaw ,
A. Malleson ,
E. Eccleston  and
G. Gundy
A. Coppen
Affiliation:
Neuropsychiatric Research Unit, Medical Research Council, West Park Hospital, Epsom, Surrey and Carshalton, Surrey
D. M. Shaw
Affiliation:
Neuropsychiatric Research Unit, Medical Research Council, West Park Hospital, Epsom, Surrey and Carshalton, Surrey
A. Malleson
Affiliation:
Neuropsychiatric Research Unit, Medical Research Council, West Park Hospital, Epsom, Surrey and Carshalton, Surrey
E. Eccleston
Affiliation:
Neuropsychiatric Research Unit, Medical Research Council, West Park Hospital, Epsom, Surrey and Carshalton, Surrey
G. Gundy
Affiliation:
Psychiatric Unit, St. George's Hospital, London, S.W.I
Get access Rights & Permissions [Opens in a new window]

Extract

In a previous investigation we showed that large doses of DL-tryptophan (214 mg./kg. body weight) given to depressed patients receiving tranylcypromine (a monoamine oxidase inhibitor) potentiated the antidepressive effects of the drug (Coppen, Shaw and Farrell, 1963). This procedure increases the level of brain 5-hydroxytryptamine (5 HT) and tryptamine in the rat (Hess and Doepfner, 1961). Reserpine reduces the level of these amines in the brain, and it is known that patients being treated for hypertension with this drug often become depressed. Thus there is evidence that increasing certain brain amines may alleviate, and depleting brain amines may induce, a depressive illness. We therefore decided to study tryptophan metabolism in depressed patients. The pathways with which we were concerned are shown below.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 111 , Issue 479 , October 1965 , pp. 993 - 998
Copyright
Copyright © Royal College of Psychiatrists, 1965 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., and Erbaugh, J. (1961). “An inventory for measuring depression” Arch. gen. Psychiat., 4, 561–571.CrossRefGoogle Scholar
Beckett, A. H., Rowland, M., and Turner, P. (1965). “Influence of urinary pH on excretion of amphetamine” Lancet, i, 303.CrossRefGoogle Scholar
Coppen, A., Shaw, D. M., and Farrell, J. P. (1963). “Potentiation of the anti-depressive effect of a monoamine–oxidase inhibitor by tryptophan” Lancet, i, 79–81.CrossRefGoogle Scholar
Coppen, A., Shaw, D. M., and Malleson, A. (1965). “Changes in 5-hydroxytryptophan metabolism in depression” Brit. J. Psychiat., 111, 105–107.CrossRefGoogle Scholar
Green, H., and Sawyer, J. L. (1960). “Correlation of tryptamine-induced convulsions in rats with brain tryptamine concentration” Proc. Soc. exp. Biol. and Med., 104, 153–155.CrossRefGoogle Scholar
Hess, S. M., and Doepfner, W. (1961). “Behavioral effects and brain amine content in rats” Arch, intern. Pharmacodyn., 134, 89–99.Google Scholar
Kline, N. S., Sacks, W., and Simpson, G. M. (1964). “Further studies on one day treatment of depression with 5-HTP” Amer. J. Psychiat., 121, 379–381.CrossRefGoogle Scholar
La Brosse, E. H., Kopin, I. J., Felix, W. R., and Westlake, R. J. (1964). “Urinary tryptamine and indole-3-acetic acid excretion by schizophrenic patients: use of the tryptamine/indole acetic acid ratio as an index of monoamine oxidase inhibition” J. psychiat. Res., 2, 185–197.CrossRefGoogle Scholar
Malleson, A. (1965). To be published.Google Scholar
Metcalfe, M., and Goldman, E. (1965). “Validation of an inventory for measuring depression” Brit. J. Psychiat., 111, 240–242.CrossRefGoogle Scholar
Oates, J. A. (1961). “Measurement of urinary tryptamine, tyramine and serotonin” Methods in Medical Research, 9, 169–174.Google Scholar
Sharman, D. F. (1965). “Metabolism of tryptamine and related compounds in the central nervous system” Brit. med. Bull., 21, 62–64.CrossRefGoogle Scholar
Sjoerdsma, A., Oates, J. A., Zaltzman, P., and Udenfriend, S. (1959). “Identification and assay of urinary tryptamine: Application as an index of monoamine oxidase inhibition in man” J. Pharmacol. and exp. Therap., 126, 217–222.Google Scholar
Tedeschi, D. H., Tedeschi, R. E., and Fellows, E. J. (1959). “The effects of tryptamine on the central nervous system, including a pharmacological procedure for the evaluation of iproniazid-like drugs” J. Pharmacol. and exp. Therap., 126, 223–232.Google Scholar
Weissbach, H., King, W., Sjoerdsma, A., and Udenfriend, S. (1959). “Formation of indole-3-acetic acid and tryptamine in animals” J. biol. Chem., 234, 81–86.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.